secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001558370-24-008556
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock initiates Phase 2 EMBRAZE obesity trial; SRK-439 preclinical data shows superiority over anti-ActRII
--------------------------------------------------------------------------------

- Phase 2 EMBRAZE proof-of-concept trial initiated for apitegromab in obesity, targeting 100 subjects on GLP-1 RA; primary data expected mid-2025.
- Preclinical head-to-head: SRK-439 at 1 mg/kg preserved lean mass equivalent to anti-ActRII at 20 mg/kg; all doses showed superiority.
- Loan Amendment No. 4 extends interest-only period to May 2025, modifies milestones for $25M additional tranche available through Dec 2024.
- SRK-439 attenuated lean mass loss to 4.2% at 10 mg/kg vs. 14.1% with IgG control + semaglutide in DIO mice.
- Company hosts Investor Day; anticipates IND filing for SRK-439 in 2025 after EMBRAZE results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/0001558370-24-008556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/srrk-20240517x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer